cardiovascular benefits of glp-1 Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Frontiers | Glucagon-like peptide-1 receptor

The first peptide polyagonist that was officially approved for T2DM and obesity was tirzepatide (LY3298176), a dual GLP-1/GIP receptor agonist which is currently under investigation in RCTs for obesity and NAFLD [7]

Lastly, a meta-analysis for changes in HbA1c between pre- and post-treatment was performed, excluding the articles with a treatment period of less than 12 weeks, as a short-term period is insufficient to assess HbA1c

Studies have found that insulin-like growth factor-1 can cause blood sugar levels to decrease, as well as improve insulin sensitivity and blood lipids in type 2 diabetic patients

This meant the cases had to go the American Arbitration Association (AAA)

Low vitamin D was also associated with cirrhosis and mortality after one year